As per DelveInsight, the Thrombocytopenia market size in the 7MM was observed to be USD 4,412 million in 2021, which is expected to grow by 2032. The market is expected to show positive growth owing to the increasing cases, improvement in research and development activities, and the launch of pipeline therapies. The rise in the cases of Thrombocytopenia stimulates the research and development of therapies, as it is likely to provide an appropriate environment for newer products to be profitable. Advances in mechanisms have yielded new diagnostic and therapeutic approaches, opening the way to more medicine development. Some of the major pharma and biotech giants in the Thrombocytopenia Market include Sanofi, Principia Biopharma, Baxalta, Takeda, Argenx, Millennium Pharmaceuticals, Biotest, GC Pharma, Genosco (Subsidiary of Oscotec), Rigel Pharmaceuticals, Kissei Pharmaceutical, Shionogi & Co., Ltd, Amgen, Novartis, Zenyaku Kogyo, and others.
DelveInsight’s “Thrombocytopenia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Thrombocytopenia market size, share, trends, and growth opportunities in the seven major markets (7MM) [i.e., the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
The Thrombocytopenia market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Thrombocytopenia: An Overview
Thrombocytopenia is a medical condition in which the platelet count in the blood falls (<150,000/µL of circulating blood) below the normal value. The etiology of thrombocytopenia is vast, as many conditions may lead to low platelet count in the blood. The most common etiologies are heparin-induced thrombocytopenia, chemotherapy-induced thrombocytopenia, thrombocytopenia associated with chronic liver disease, immune thrombocytopenia (ITP), and thrombotic thrombocytopenic purpura (TTP).
Thrombocytopenia often improves when its underlying cause is treated. People who inherit the condition do not usually need treatment. If a reaction to a medicine is causing a low platelet count, the doctor may prescribe another medicine. Most people recover after the initial medicine has been stopped. For heparin-induced thrombocytopenia (HIT), stopping the heparin is not enough. Often, the patients need another medicine to prevent blood clotting. If the immune system is causing a low platelet count, the doctor may prescribe medicines to suppress the immune system.
Latest Key Update in the Thrombocytopenia Market
On April 06, 2023, Rallybio Corporation (Nasdaq: RLYB) announced the publication of Phase 1 / 2 proof-of-concept results for RLYB211, a polyclonal anti-HPA-1a antibody derived from human plasma for the prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT). There are currently no approved therapies for the prevention or treatment of FNAIT. The findings were published in the Journal of Thrombosis and Haemostasis, the official journal of the International Society on Thrombosis and Haemostasis.
Thrombocytopenia Market Key Facts
- In 2021, the US has the largest Thrombocytopenia market size of USD 2,447 million among the 7MM countries.
- Among the EU-5 countries, Germany had the highest Thrombocytopenia market size in 2021, i.e., USD 431 million. The lowest Thrombocytopenia market size was estimated in France, with USD 242 million in 2021.
- In Japan, the Thrombocytopenia market size was observed to be USD 328 million in 2021.
- In 2021, the total number of cases of Thrombocytopenia in the 7MM countries were 2,608,095, and these cases are anticipated to increase during the study period.
- The US had 1,045,247 cases of Thrombocytopenia in 2021.
- Among the European countries, Germany had the highest number of cases of Thrombocytopenia in 2021, i.e., 453,441 cases, followed by the UK, which had 269,422 cases in 2021. On the other hand, Italy had the lowest number of cases of Thrombocytopenia, i.e., 127,166 cases in 2021.
- Japan, in 2021, accounted for 58,261 cases of Chemotherapy-induced Thrombocytopenia, which is expected to increase during the study period.
Learn How Thrombocytopenia Market Dynamics are Changing with Ongoing Therapeutic Developments in the Domain @ Thrombocytopenia Therapeutics Market Analysis
Thrombocytopenia Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Thrombocytopenia market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Thrombocytopenia market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Thrombocytopenia Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Thrombocytopenia Epidemiology Segmented by –
- Total Cases of Thrombocytopenic Purpura (TTP) in the 7MM [2019-2032]
- Total Cases of Thrombocytopenia in the 7MM [2019-2032]
- Total Cases of Immune Thrombocytopenia (ITP) in the 7MM [2019-2032]
- Total Cases of Chemotherapy-induced Thrombocytopenia in the 7MM [2019-2032]
- Total Number of Cases of Heparin-induced Thrombocytopenia in the 7MM[2019-2032]
- Total Cases of Thrombocytopenia in Chronic Liver Disease in the 7MM [2019-2032]
Explore how Thrombocytopenia Epidemiology is Evolving in the 7MM @ Thrombocytopenia Epidemiology Trends
Thrombocytopenia Drugs Uptake and Pipeline Development Activities
The drugs’ uptake section focuses on the rate of uptake of the potential drugs recently launched in the Thrombocytopenia market or expected to get launched during the study period. The analysis covers the Thrombocytopenia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Thrombocytopenia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Thrombocytopenia Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Thrombocytopenia. Currently, Argenx is leading the therapeutic market with its Thrombocytopenia drug candidates in the most advanced stage of clinical development.
Some of the Key Companies in the Thrombocytopenia Therapeutics Market Include:
Amgen, Argenx, Baxalta, Biotest, GC Pharma, Genosco (Subsidiary of Oscotec), HUTCHMED, Keros Therapeutics, Kissei Pharmaceutical, Millennium Pharmaceuticals, Momenta Pharmaceuticals, Novartis, Pfizer, Principia Biopharma, Rigel Pharmaceuticals, Sanofi, Shionogi & Co., Ltd, Sobi (Dova Pharmaceuticals), Takeda, UCB, Veralox Therapeutics, Zenyaku Kogyo, and many others.
Thrombocytopenia Emerging and Marketed Drugs Covered in the Report Include:
- BIVV020: Sanofi
- CABLIVI (Caplacizumab/ALX-0081): Sanofi (Ablynx)
- Cevidoplenib: Genosco
- DOPTELET (Avatrombopag): Sobi (Dova Pharmaceuticals)
- Efgartigimod (ARGX-113): Argenx
- GC5101B (GC5107A, IV-Globulin SN Inj. 10%): GC Pharma
- MULPLETA/MULPLEO (Lusutrombopag): Shionogi & Co., Ltd.
- NPLATE (Romiplostim, Amg-531): Amgen
- PROMACTA (Eltrombopag): Novartis
- Rilzabrutinib (PRN-1008): Sanofi/Principia Biopharma
- RITUXAN (Rituximab): Zenyaku Kogyo
- Rozanolixizumab: UCB
- SKI-O-703: Genosco (Subsidiary of Oscotec)
- Sovleplenib: HUTCHMED
- TAK-079: Millennium Pharmaceuticals/Takeda
- TAK-755 (BAX930/SHP655): Baxalta/Takeda
- TAVALISSE (Fostamatinib): Rigel Pharmaceuticals/Kissei Pharmaceutical
And Many More
In-depth Details of the Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More @ Thrombocytopenia Therapeutic Market Outlook
Scope of the Thrombocytopenia Market Report:
- Study Period – 2019-2032
- Geography Covered – 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
- Key Companies In the Market Include –
- Marketed and Emerging Drugs –
- Competitive Intelligence Analysis – SWOT Analysis, PESTLE Analysis, Porter’s Five Forces, BCG Matrix, Market Entry Strategies
Visit to Get More Key Insights @ Thrombocytopenia Market Trends and Developments
Table of Content
| 1 | Report Introduction |
| 2 | Key Insights |
| 3 | Executive summary |
| 4 | Thrombocytopenia Competitive Intelligence Analysis |
| 5 | Thrombocytopenia Market Overview at a Glance |
| 6 | Thrombocytopenia Disease Background and Overview |
| 7 | Thrombocytopenia Patient Journey |
| 8 | Thrombocytopenia Epidemiology and Patient Population (In the US, EU5, and Japan) |
| 9 | Thrombocytopenia Treatment Algorithm, Current Treatment, and Medical Practices |
| 10 | Thrombocytopenia Unmet Needs |
| 11 | Key Endpoints of Thrombocytopenia Treatment |
| 12 | Thrombocytopenia Marketed Products |
| 13 | Thrombocytopenia Emerging Drugs and Latest Therapeutic Advances |
| 14 | Thrombocytopenia Seven Major Market Analysis |
| 15 | Attribute Analysis |
| 16 | Thrombocytopenia Market Outlook (In US, EU5, and Japan) |
| 17 | Thrombocytopenia Access and Reimbursement Overview |
| 18 | KOL’s Views on the Thrombocytopenia Market |
| 19 | Thrombocytopenia Market Drivers |
| 20 | Thrombocytopenia Market Barriers |
| 21 | Appendix |
| 22 | DelveInsight Capabilities |
| 23 | Disclaimer |
Download the Sample PDF to Explore More About the Key Offerings of the Report @ Thrombocytopenia Therapeutics Market Outlook and Forecast 2032
Related Reports
Thrombocytopenia Pipeline Insight
“Thrombocytopenia Pipeline Insight 2023” report provides comprehensive insights about 25+ companies and 25+ drugs in Thrombocytopenia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by stage, route of administration, and molecule type.
Thrombocytopenia Epidemiology Forecast
“Thrombocytopenia Epidemiology Forecast 2032’ report delivers an in-depth understanding of the historical and forecasted epidemiology trends in the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Chemotherapy-induced Thrombocytopenia (CIT) Market
“Chemotherapy-induced Thrombocytopenia (CIT) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Chemotherapy-induced thrombocytopenia (CIT) market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Thrombotic Thrombocytopenic Purpura Market
“Thrombotic Thrombocytopenic Purpura Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Thrombotic Thrombocytopenic Purpura market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Idiopathic Thrombocytopenic Purpura Market
“Idiopathic Thrombocytopenic Purpura Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Idiopathic Thrombocytopenic Purpura market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Trending Reports:
- Menorrhalgia Market
- Complicated Intra-Abdominal Infections market
- Bronchial Spasm Market
- Acute Radiation Syndrome Market
- Age Related Vision Dysfunction Market
- Cerebral Aneurysm Market
Leverage the potential of consulting services to overcome the competition in the highly evolving and dynamic healthcare market with DelveInsight’s Healthcare Portfolio Management Solutions and Healthcare Partner Identification Solutions.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Contact Us
Shruti Thakur
Manager (Marketing & Branding)
info@delveinsight.com
+1(919)321-6187